

EUROPEAN LUNG CANCER CONFERENCE 2016

CHARACTERIZATION OF TUMOR INFILTRATING LYMPHOCYTES IN RESECTABLE EARLY-STAGE NON-SMALL CELL LUNG CANCER

Sean Hall
Division of Thoracic Surgery,
University Hospital of Bern



UNIVERSITÄTSSPITAL BERN HOPITAL UNIVERSITAIRE DE BERNE BERN UNIVERSITY HOSPITAL

DISCLOSURE SLIDE

The authors have no financial or commercial interests to disclose



NON-SMALL CELL LUNG CANCER (NSCLC)

- Leading cause of cancer deaths worldwide⁽¹⁾
- Platinum-based doublet chemotherapy in advanced metastatic disease


- 'Non-immunogenic' tumor
- Immune checkpoint pathway and adaptive resistance mechanisms

1. CA Cancer J. Clin. 64(1), 9-29: 2014



IMMUNE CHECKPOINT PATHWAY: DOMINATE ROLE IN T CELL SUPPRESSION

Protects from over-exuberant T cell responses




Zou et al. Science Transl. Med. 2016 (8) 328

High levels of PD-1 TILs in various cancer types




Aim: Immunophenotype TILs in resectable early-stage NSCLC



Pipeline showing workflow study design




Characteristic	Value
Age –yr	
Median	64
range	48-84
Sex - no. (%)	
Female	26 (40)
male	40 (60)
Smoke status – no. (%)	
Smoker	42 (64)
Never smoker	10 (15)
Not reported	14 (21)
Tumor Type – no. (%)	
NSCLC	
Adeno	33 (50)
Squamous	33 (50)
Tumor Grade – no. (%)	
None	10 (15)
G2	26 (39)
G3	30 (45)
G4	0 (0)
T (0/)	
Tumor Stage – no. (%)	14 (01)
IA IIA	14 (21)
I IIA I IIIA	10 (15)
IB	19 (29) 11 (17)
IIB	
IV	8 (12) 2 (3)
none	2 (3)
Prior Tx – no. (%)	2 (0)
Yes	10 (15)
No	56 (85)
	33 (33)






EUROPEAN LUNG CANCER CONFERENCE 2016


TIL Immunophenotype








TIL subpopulations: Evidence of exhaustion in Adenocarcinoma



Adenocarcinoma, N=33, paired t-test, two sided



TIL subpopulations: Evidence of exhaustion in Squamous cell carcinoma



Squamous, N=33, paired t-test, two sided



Resectable, early-stage NSCLC

- Impaired infiltration of TILs
- Decrease in CD8+ TILs whereas CD4+ TILs increased in Adenocarcinoma
- PD-1^{hi} TILs show phenotypic markers of exhaustion
- B cells and PD-1

WHERE DO WE GO FROM HERE?

- PD-1^{hi} TILs, tumor-specific antigens and mutational load
- PD-1 inhibition with targeted, chemo- and radiation therapy





UNIVERSITÄTSSPITAL BERN HOPITAL UNIVERSITAIRE DE BERNE BERN UNIVERSITY HOSPITAL





DEPARTMENT OF CLINICAL RESEARCH

Contacts ESMO

European Society for Medical Oncology Via L. Taddei 4, CH-6962 Viganello – Lugano T. +41 (0)91 973 19 00 F. +41 (0)91 973 19 02

http://www.esmo.org esmo@esmo.org

University Hospital Bern, Thoracic Surgery

Ralph Schmid

Patrick Dorn

Thomas Marti

Ren-Wang Peng

Laurène Froment

Limei Wang

Andreas Keil

Colin Tièche

Simon Liang

Ming Qiao

Greg Kocher

University of Bern, Department of Pathology

Sabina Berezowska

